Patents Assigned to Henry Jackson Foundation
-
Patent number: 10342871Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.Type: GrantFiled: October 22, 2015Date of Patent: July 9, 2019Assignees: The Henry Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
-
Publication number: 20150045240Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.Type: ApplicationFiled: February 28, 2014Publication date: February 12, 2015Applicant: Henry Jackson Foundation for the Advancement of Military ScienceInventors: Gyorgy Petrovics, Shiv Srivastava
-
Patent number: 8313746Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: August 1, 2011Date of Patent: November 20, 2012Assignees: The Henry Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as Represented by the Secretary of the Department of Health and Human Services National Institutes of Health, Office of Technology TransferInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
-
Patent number: 6455593Abstract: The invention relates to a method of potentiating cell damage in a target cell population by administering a “restraining agent” and concomitantly or subsequently applying a “targeted cytotoxic insult.” The restraining agent is administered at a concentration and under conditions sufficient to retard, but not to arrest, the progress of the target cell population through the cell cycle, a concept termed “dynamic retardation.” With such a mechanism, all the cells intended for damage by the targeted cytotoxic insult are likely to cycle into the relevant interval of vulnerability (target interval) within the cell cycle, resulting in a larger number of susceptible cells, and the time period during which those cells are vulnerable to the action of a given targeted cytotoxic insult is increased, resulting in a higher probability and percentage of cell killing.Type: GrantFiled: February 8, 2001Date of Patent: September 24, 2002Assignee: The Henry Jackson Foundation for the Advancement of Military MedicineInventors: Philip M. Grimley, Sunil Mehta
-
Patent number: 6274576Abstract: The invention relates to a method of potentiating cell damage in a target cell population by administering a “restraining agent” and concomitantly or subsequently applying a “targeted cytotoxic insult.” The restraining agent is administered at a concentration and under conditions sufficient to retard, but not to arrest, the progress of the target cell population through the cell cycle, a concept termed “dynamic retardation.” With such a mechanism, all the cells intended for damage by the targeted cytotoxic insult are likely to cycle into the relevant interval of vulnerability (target interval) within the cell cycle, resulting in a larger number of susceptible cells, and the time period during which those cells are vulnerable to the action of a given targeted cytotoxic insult is increased, resulting in a higher probability and percentage of cell killing.Type: GrantFiled: October 8, 1998Date of Patent: August 14, 2001Assignee: The Henry Jackson Foundation for the Advancement of Military MedicineInventors: Philip M. Grimley, Sunil Mehta
-
Patent number: 5955079Abstract: A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, treatment, and prevention of diseases.Type: GrantFiled: June 6, 1995Date of Patent: September 21, 1999Assignee: Henry Jackson Foundation for the Advancement of Military MedicineInventors: James J. Mond, Andrew Lees
-
Patent number: 5585100Abstract: A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, treatment, and prevention of diseases.Type: GrantFiled: March 13, 1995Date of Patent: December 17, 1996Assignee: Henry Jackson FoundationInventors: James J. Mond, Andrew Lees